Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
26 mars 2019 06h00 HE
|
Autolus Therapeutics plc
LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the...
Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters
09 juil. 2018 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
26 juin 2018 08h00 HE
|
7 Hills Pharma
HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today the formation...
7 Hills Pharma Launches With $2 Million SBIR Grant in Addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance
19 juin 2018 08h00 HE
|
7 Hills Pharma
HOUSTON, June 19, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today that it has...
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital
11 juin 2018 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics
03 avr. 2018 17h00 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., April 03, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (“Unum Therapeutics”) (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on the development of novel...
Unum Therapeutics Announces Pricing of Initial Public Offering
28 mars 2018 21h35 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX) (“Unum Therapeutics”), a clinical-stage biopharmaceutical company focused on the development of novel...
Nkarta Therapeutics Appoints Veteran Executive Paul Hastings as CEO to Lead Next Phase of Growth
01 mars 2018 14h05 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing natural killer (NK) immune cells to fight cancer, announced that...
Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco
05 janv. 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...